Please use this identifier to cite or link to this item:
Title in Portuguese: α-Lipoic acid as adjunctive treatment for schizophrenia : an open-label trial
Author: Sanders, Lia Lira Olivier
Menezes, Carlos Eduardo de Souza
Chaves Filho, Adriano José Maia
Viana, Glautemberg de Almeida
Fechine, Francisco Vagnaldo
Queiroz, Maria Goretti Rodrigues de
Fonseca, Said Gonçalvez da Cruz
Vasconcelos, Silvânia Maria Mendes
Moraes, Maria Elisabete Amaral de
Gama, Clarissa S.
Seybolt, Sheila
Campos, Eugênio de Moura
Macêdo, Danielle
Lucena, David Freitas de
Keywords: Esquizofrenia
Issue Date: Dec-2017
Publisher: Journal of Clinical Psychopharmacology
Citation: SANDERS, L. L. O et al. α-Lipoic acid as adjunctive treatment for schizophrenia: an open-label trial. Journal of Clinical Psychopharmacology, Baltimore, v. 37, n. 6, p. 697–701, dec. 2017.
Abstract: Purpose/Background: Accumulating evidence suggests an involvement of oxidative stress in the pathophysiology of schizophrenia. This offers a hypothesis-derived therapeutic approach to hinder oxidative damage and its clinical sequelae. α-Lipoic acid (ALA) is a powerful natural antioxidant indicated to treat diabetic neuropathy. Methods/Procedures: In this pilot investigation, we administered ALA (100 mg/d) for 4 months, as an adjunct to antipsychotic medication, to 10 patients with schizophrenia. Findings/Results: We found robust improvement in measures of psychopathology (63.9% reduction in Brief Psychiatric Rating Scale scores), neurocognitive parameters, extrapyramidal symptoms, and decreased lipid peroxidation. Implications/Conclusions: If larger, double-blind, placebo-controlled studies confirm these preliminary findings, ALA could prove useful as adjunctive therapy for schizophrenia.
metadata.dc.type: Artigo de Periódico
ISSN: 0271-0749
1533-712X (Online)
Appears in Collections:DFAR - Artigos publicados em revistas científicas

Files in This Item:
File Description SizeFormat 
2017_art_llosanders.pdf132,33 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.